ProCE Banner Activity

How I Adapt My Clinical Practice to New Approaches for Relapsed/Refractory Multiple Myeloma

Clinical Thought
With many recent changes in treatment options for relapsed/refractory MM, it can be hard to keep up. In this commentary, I review some of the most important new approaches for patients with relapsed/refractory MM.

Released: January 23, 2017

Expiration: January 22, 2018

No longer available for credit.

Share

Faculty

Kenneth Anderson

Kenneth Anderson, MD

Kraft Family Professor of Medicine
Harvard Medical School
Director, Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Takeda Oncology

Faculty Disclosure

Primary Author

Kenneth Anderson, MD

Kraft Family Professor of Medicine
Harvard Medical School
Director, Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Kenneth Anderson, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Celgene, Gilead Sciences, and Millennium and holds ownership interest in Acetylon, C4 Therapeutics, and OncoPep.